Wall Street analysts’ outlook for United Therapeutics Corp (UTHR)

With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $231.02 whereas the lowest price it dropped to was $225.62. The 52-week range on UTHR shows that it touched its highest point at $261.54 and its lowest point at $204.44 during that stretch. It currently has a 1-year price target of $291.75. Beta for the stock currently stands at 0.55.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UTHR was down-trending over the past week, with a drop of -6.42%, but this was down by -1.44% over a month. Three-month performance surged to 3.95% while six-month performance rose 1.20%. The stock gained 4.37% in the past year, while it has gained 3.95% so far this year. A look at the trailing 12-month EPS for UTHR yields 19.84 with Next year EPS estimates of 24.37. For the next quarter, that number is 5.79. This implies an EPS growth rate of 18.78% for this year and 3.56% for next year. EPS is expected to grow by 9.70% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 8.15%.

Float and Shares Shorts:

At present, 47.04 million UTHR shares are outstanding with a float of 43.37 million shares on hand for trading. On Mar 15, 2024, short shares totaled 1.92 million, which was 4.08% higher than short shares on Feb 15, 2024. In addition to Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. as the firm’s Founder, Chairman & CEO, Mr. Michael I. Benkowitz serves as its President & COO.

Institutional Ownership:

Through their ownership of 97.02% of UTHR’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for UTHR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, UTHR has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and UTHR currently yields $0.00. In the past year, UTHR’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, UTHR has a current buyback yield of $0.13. This was $0.13 for the TTM, and it was $0.09 for the past five years.